Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 56 (TRAJ56) is one of the joining (J) gene segments within the T cell receptor alpha locus in humans[2][3][4][7]. The TRAJ56 gene segment does not encode a standalone functional protein or receptor but instead serves as a genetic building block that contributes to forming the variable region of the T cell receptor alpha (TRA) chain through somatic recombination during T cell development[5][8]. The full T cell receptor is a heterodimeric complex (usually alpha and beta chains), crucial for T cell recognition of antigens presented by the major histocompatibility complex (MHC)[5][7][8]. TRAJ56 itself is not considered a receptor, enzyme, transporter, or direct therapeutic target but is part of the genetic mechanism creating T cell diversity. Clarification: TRAJ56 is a gene segment, not a full protein/receptor, and does not function independently as a therapeutic target. It cannot be directly targeted by drugs, nor does it serve as a biomarker or have a direct role in disease or drug mechanism. Its relevance is strictly genomic, as a component part of T cell receptor diversity[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 56 (TRAJ56).